Phase I study of ITI-1020 in healthy volunteers
Latest Information Update: 14 Mar 2023
At a glance
- Drugs Lumateperone (Primary)
- Indications Alzheimer's disease; Psychotic disorders
- Focus Adverse reactions
Most Recent Events
- 14 Mar 2023 New trial record
- 01 Mar 2023 According to Intra-cellular media release, phase I study of ITI-1020 is expected to commence in 1H of 2023.